Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Shuford

Urology Dallas, TX Medical Doctor

NPI 1710932140 CMS profile 304314

3417 Gaston Ave, Suite 830, Dallas, TX 75246

Open in the dashboard

General payments

$8,309

334 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Shuford of Dallas, TX is reported in the CMS Open Payments database as having received $8,309 across 334 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,024 86
2024 General $2,164 66
2023 General $895 46
2022 General $1,133 45
2021 General $728 28
2020 General $234 14
2019 General $1,132 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Shuford
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Matthew Shuford were reported at $2,024. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Matthew Shuford Urology median Middle half National median
2019 $1,132 $480 $147–$1,201 $163
2020 $234 $246 $87–$645 $114
2021 $728 $358 $111–$1,000 $132
2022 $1,133 $476 $143–$1,263 $149
2023 $895 $560 $168–$1,461 $160
2024 $2,164 $563 $170–$1,464 $164
2025 $2,024 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dendreon Pharmaceuticals LLC $793 33 payments
  2. Edap Technomed Inc $735 3 payments
  3. Sumitomo Pharma America, Inc. $674 41 payments
  4. Astellas Pharma US Inc $597 36 payments
  5. Janssen Biotech, Inc. $555 25 payments
  6. Urogen Pharma, Inc. $425 6 payments
  7. Boston Scientific Corporation $410 17 payments
  8. AbbVie, Inc. $349 12 payments
  9. Blue Earth Diagnostics Limited $266 14 payments
  10. Immunitybio, Inc. $261 8 payments
  11. Other $3,244 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,222 331 payments
  2. Education $88 3 payments
Products named General payments · program years 2019–2025
  1. PROVENGE $793 33 payments
  2. ERLEADA $549 24 payments
  3. XTANDI $450 28 payments
  4. GEMTESA $317 33 payments
  5. ORGOVYX Prostate Cancer $284 7 payments
  6. LUPRON DEPOT $275 8 payments
  7. MYRBETRIQ $267 14 payments
  8. ORGOVYX Hormone Therapy $229 9 payments
  9. ANKTIVA $229 7 payments
  10. Xofigo $225 11 payments
  11. Other $4,103 186 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

3,455

Median for Urology: 1,053

Drug cost

$4,230,152

Median for Urology: $101,464

Branded share of claims

33.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 173 $2,424,077
Erleada Apalutamide Brand 49 $744,687
Orgovyx Relugolix Brand 243 $628,466
Nubeqa Darolutamide Brand 16 $214,815
Myrbetriq Mirabegron Brand 111 $79,008
Gemtesa Vibegron Brand 72 $65,342
Tamsulosin Hcl Generic 900 $13,211
Finasteride Generic 857 $12,981
Testosterone Generic 74 $10,535
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 63 $7,081

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$663,099

Of which drugs: $221,159

Medicare patients

1,055

Average age 75

Services billed

20,751

120 women, 935 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 45%
Arthritis 42%
Ischemic heart disease 32%
Diabetes 24%
Chronic kidney disease 22%
Atrial fibrillation 19%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 11 6,540 $135,073
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 32 312 $44,153
Injection, ceftriaxone sodium, per 250 mg J0696 Office 37 148 $53

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $108
  • PFIZER INC. $9
$117 243 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $98
$98 — —
ERLEADA
  • Janssen Biotech, Inc. $93
$93 49 —
GEMTESA
  • Sumitomo Pharma America, Inc. $83
$83 72 —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record